Bradmer Pharmaceuticals Inc. (TSE:GLX – Get Free Report) has earned a consensus recommendation of “Strong Buy” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and six have issued a strong buy rating on the company.
Separately, Citizens Jmp raised Bradmer Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, December 9th.
View Our Latest Stock Analysis on GLX
Bradmer Pharmaceuticals Price Performance
Further Reading
- Five stocks we like better than Bradmer Pharmaceuticals
- The day the gold market broke
- Forget AI, This Will Be the Next Big Tech Breakthrough
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- Gold’s getting scarce.
- End of America Update
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
